Video

Dr. Boland on Leveraging Triplet Chemo Regimens in Non-Resectable Liver-Only mCRC

Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.

Patrick Boland, MD, medical oncologist, member of the gastrointestinal oncology team, active member of the NCI National Clinical Trial Network, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer (mCRC).

Treatment options keep expanding for patients whose disease is not initially resectable, according to Boland. The use of triplet chemotherapy regimens has increased in recent years, and regimens such as FOLFOXIRI or FOLFIRINOX have induced high response rates in this population, Boland adds. 

Furthermore, data have shown that the addition of bevacizumab (Avastin) to FOLFOX has resulted in improved response rates and can protect the liver in patients with liver-only mCRC, Boland adds. As more is learned about these therapies and more options become available, the challenge will be determining the optimal amount and duration of these agents, Boland concludes. 

Related Videos
David Samuel Dicapua Siegel, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
 Philip McCarthy, MD
Lova L. Sun, MD, MSCE
Robert M. Rifkin, MD, FACP
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
Andrew Ip, MD
Anthony B. El-Khoueiry, MD